The Weill Cancer Hub East has been established to explore the “interplay” between nutrition and immunotherapy in cancer ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 ...

Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary ...

Ending clinical trials with no warning can put patients at risk.

The hub will evaluate how emerging therapeutics, including GLP-1 agonists, might impact cancer progression and treatment.

March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like ...

Cancer screening tests can be divided into early detection and preventive tests.1 Early-detection tests (eg, mammography for ...

Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...